Mcgill University Health Centre/research Institute Of The Mcgill University Health Centre
Clinical trials sponsored by Mcgill University Health Centre/research Institute Of The Mcgill University Health Centre, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Bubble noises may hold key to safer breathing support for preemies Results expected Sep 2026 (estimated)
- New app aims to cut endometriosis diagnosis delays by improving Patient-Doctor talks Results expected Sep 2026 (estimated)
- Breastfeeding women finally included in TB drug research Results expected Oct 2026 (estimated)
- Could a finger prick replace the needle for inflammation tests? Results expected Dec 2026 (estimated)
- New pacing technique aims to cut heart failure risk Results expected Dec 2026 (estimated)
-
Early lung cancer drug combo trial halted after just 6 patients
Disease control Stopped earlyThis study looked at giving the immunotherapy drug pembrolizumab (Keytruda) alone or with chemotherapy before surgery for people with early-stage non-small cell lung cancer. The goal was to see if these treatments could shrink tumors and improve outcomes. However, the trial was s…
Phase 2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Stem cell shot for COVID-19 fizzles in small trial
Disease control Stopped earlyThis study tested whether a single infusion of stem cells from umbilical cord tissue (ProTrans®) could help hospitalized adults with severe COVID-19 avoid ventilators or death. The trial was stopped early after enrolling only 19 people, so we cannot draw firm conclusions. Both th…
Phase 2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
Lung disease drug tested in rare muscle condition – trial cut short
Disease control Stopped earlyThis study tested the drug nintedanib (Ofev) in 11 people with myositis-related interstitial lung disease, a condition where lung scarring occurs alongside muscle inflammation. The goal was to see if the drug is safe and tolerable when added to standard immune-suppressing treatme…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC
-
Opioid trial for COPD breathlessness halted early
Symptom relief Stopped earlyThis study tested whether a low dose of fentanyl, a strong painkiller, placed under the tongue could help people with severe COPD feel less breathless during exercise. The trial planned to include 40 participants but was stopped early. Because it was terminated, we cannot draw cl…
Phase 2/3 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Symptom relief
Last updated Jun 27, 2026 09:11 UTC